BioSpace News Archive

Integra LifeSciences Holding Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it entered into a definitive agreement to acquire Surgical Innovation Associates (SIA), which develops, markets and sells DuraSorb®, a resorbable synthetic matrix for plastic and reconstructive surgery.

Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5).

Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma.

WishBone Medical, Inc., a leader in pediatric orthopedic medical devices, announced the procurement of additional growth capital as well as changes to executive leadership, including the appointment of Dr. Mark Figgie as Interim Chief Executive Officer.

Roivant Sciences (Nasdaq: ROIV) and Pfizer Inc. today announced formation of a new Vant to develop and commercialize PF-06480605 (now RVT-3101).

Rapid Micro Biosystems, Inc., an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced that its Board of Directors has concluded its previously announced review of strategic alternatives.

Hoffmann-La Roche Limited (Roche Canada) announced today that it has signed agreements with the Government of Canada to supply 15,000 treatment courses of ACTEMRA ® IV (tocilizumab for injection) for adult patients hospitalized with COVID-19.

Kintara Therapeutics, Inc. today announced that Robert E. Hoffman, President and CEO of Kintara, will be participating at the RHK Capital Disruptive Growth Conference in New York City.

SHL Telemedicine Ltd. today announced that it will be presenting virtually at the upcoming Ladenburg Thalmann Virtual Technology Expo on Wednesday, December 7th, at 9:30 AM ET / 3:30 PM CET.

DarioHealth Corp., a leader in the global digital therapeutics market, announced that two employers selected Dario as part of an offering from a leading benefits brokerage partner that Dario had previously announced.